Somewhat Positive Press Coverage Somewhat Unlikely to Impact Atara Biotherapeutics (ATRA) Share Price

News headlines about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.9379393621922 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have effected Accern’s rankings:

• Insider Trading Activity Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – CEO Sold 2,800 shares of Stock (4-traders.com)
• Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 2,800 Shares of Stock (americanbankingnews.com)
• Isaac E. Ciechanover Sells 5,500 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock (americanbankingnews.com)
• Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Traded 12.8% Above Its 50 Day Average (highlightpress.com)

Atara Biotherapeutics (NASDAQ:ATRA) traded down 1.32% during midday trading on Friday, hitting $15.00. The company had a trading volume of 211,533 shares. The stock’s market cap is $436.64 million. The stock’s 50-day moving average price is $14.57 and its 200-day moving average price is $15.88. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $25.73.

A number of equities analysts have commented on ATRA shares. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Canaccord Genuity reissued a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a report on Friday, April 21st. Jefferies Group LLC reissued a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $25.75.

TRADEMARK VIOLATION WARNING: “[[title]]” was originally posted by [[site]] and is owned by of [[site]]. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at [[permalink]].

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 4,800 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $14.91, for a total value of $71,568.00. Following the completion of the transaction, the chief executive officer now directly owns 731,859 shares in the company, valued at approximately $10,912,017.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO John Mcgrath sold 4,000 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $15.11, for a total value of $60,440.00. Following the completion of the transaction, the chief financial officer now owns 113,762 shares of the company’s stock, valued at $1,718,943.82. The disclosure for this sale can be found here. Insiders sold a total of 54,308 shares of company stock valued at $797,382 over the last quarter. 16.10% of the stock is currently owned by insiders.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.